PER percheron therapeutics limited

0.00%

1.0¢

Ann: Notices received under s203D and s249D of Corporations Act, page-76

First 76 Last

Share
Profile

Follow
itsagas

14,657 Posts.

1583

08/01/25

11:11

Post #: 77314743
Share

Originally posted by Uboy: ↑

I just can't fathom that all the below data is now worth $0.

And was September's news release about Autoimmune Epilepsy a bridge to what was already known by Charmaine and Garner?

Where did Epilepsy come from - i thought it was pretty random at the time when all focus was on DMD.

The Proteomics blood analysis
- Statistically significant mean modulation at 24 weeks compared to baseline in Thrombospondin1 (TSP-1) and Latent TGF-beta-binding protein 4 (LTBP4) levels, two proteins that modify the rate of loss of ambulation in DMD
- Increase at 24 weeks in plasma VCAM-1 supportive of the ATL1102 mechanism of action of reducing CD49d on the surface of cells to which soluble VCAM-1 is bound, and in CXCL16 which can promote muscle regeneration
- Positive effects on LTBP4 and TSP-1 positions ATL1102 as an exciting prospect for the treatment of both non-ambulant and ambulant patients with DMD and the treatment of other muscle and fibrotic conditions

Significant modulation of two bone morphogenetic proteins supports potential of ATL1102
Statistically significant mean increases in BMP-5 (46.2%) and BMP-6 (34.4%) were observed at 24 weeks compared to baseline levels (FDR p-value <0.0005). When compared to an external healthy adult proteomics dataset used as a control, the baseline BMP-5 and BMP-6 levels of patients in the Phase II study were below average with the levels of each protein increasing to near the external healthy adult control mean by the end of the 24 week ATL1102 dosing period.

The positive DMD combo study...
RNA-seq transcriptomics results support the role of ATL1102, as monotherapy and in combination with a dystrophin exon skipping restoration agent, in reducing inflammation and augmenting muscle recovery

Limb Girdle R2 animal study - positive results...
In a mouse model of LGMDR2, treatment with ATL1102 partially normalised the function and physiology of the calf muscles to those of healthy animals.

AVICURSEN (ATL1102) shows positive signals in Autoimmune Epilepsy
Murine analogue of avicursen in a mouse model of autoimmune epilepsy showed a reduction in median seizure frequency of 66% for the drug when compared to a saline control. The reduction was statistically significant.

Expand

Thanks Uboy

Yes ..all positive indicators but a clinical trial is the only way to determine if these biological changes actually result in clinically measurable meaningful outcomes.

We need the laboratory data to confirm..

Thats why I’m saying on behalf of all
Moses and Gennadi
Wait for the Lab results before you implement this futile exercise…costing Per $$ in lawyers fees…

PER Price at posting: 0.8¢ Sentiment: Hold Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

Friday’s HotCopper trends: Dreadnoughts's drill delight, Galan's beaut raise | June 19

NVO

Novo flags antimony and gold in the Pilbara – but does it need to step back?

PV1

Hydrogen tanker stock Provaris inks MOU with "K" LINE to provide advice

Week 25 Wrap: Fed & BoE pause rates ahead of RBA; Santos-ADNOC, Oz tax reforms

AL3

AML3D opens new facility in Ohio as US Defence strategy bears fruit

HotCopper Highlights for Week 25: 4DS Memory, Meeka & Sprott-citement

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

Thursday's HotCopper trends: Second Amplia response, Race combo dosing | June 19

ASX Market Open: Stocks slide as Trump tosses up attacking Iran directly | June 20

PIQ

Proteomics notches up as company launches PromarkerD into the US

First 76 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.0¢		Change 0.000(0.00%)		Mkt cap ! $10.87M

Open	High	Low	Value	Volume
1.0¢	1.0¢	1.0¢	$727	72.68K

Buyers (Bids)

No.	Vol.	Price($)
4	2840316	1.0¢

Sellers (Offers)

Price($)	Vol.	No.
1.1¢	3323423	6

View Market Depth

No.	Vol.	Price($)
3	2740316	0.010
6	5659202	0.009
4	1260267	0.008
3	1642854	0.007
2	3200000	0.005

Price($)	Vol.	No.
0.011	3323423	6
0.012	1139598	3
0.013	1000000	1
0.014	2072000	4
0.015	1500000	1

Last trade - 12.00pm 20/06/2025 (20 minute delay)

PER (ASX) Chart

Ann: Notices received under s203D and s249D of Corporations Act, page-76

Friday’s HotCopper trends: Dreadnoughts's drill delight, Galan's beaut raise | June 19

Novo flags antimony and gold in the Pilbara – but does it need to step back?

Hydrogen tanker stock Provaris inks MOU with "K" LINE to provide advice

Week 25 Wrap: Fed & BoE pause rates ahead of RBA; Santos-ADNOC, Oz tax reforms

AML3D opens new facility in Ohio as US Defence strategy bears fruit

HotCopper Highlights for Week 25: 4DS Memory, Meeka & Sprott-citement

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

Thursday's HotCopper trends: Second Amplia response, Race combo dosing | June 19

ASX Market Open: Stocks slide as Trump tosses up attacking Iran directly | June 20

Proteomics notches up as company launches PromarkerD into the US

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Notices received under s203D and s249D of Corporations Act, page-76

Top Stories

Friday’s HotCopper trends: Dreadnoughts's drill delight, Galan's beaut raise | June 19

Novo flags antimony and gold in the Pilbara – but does it need to step back?

Hydrogen tanker stock Provaris inks MOU with "K" LINE to provide advice

Week 25 Wrap: Fed & BoE pause rates ahead of RBA; Santos-ADNOC, Oz tax reforms

AML3D opens new facility in Ohio as US Defence strategy bears fruit

HotCopper Highlights for Week 25: 4DS Memory, Meeka & Sprott-citement

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

Thursday's HotCopper trends: Second Amplia response, Race combo dosing | June 19

ASX Market Open: Stocks slide as Trump tosses up attacking Iran directly | June 20

Proteomics notches up as company launches PromarkerD into the US

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News